Comparing Melanotan 1 and Melanotan 2 Peptides - Core Peptides

Inflammation is a natural host protective phenomenon, but unchecked and prolonged inflammation may deteriorate the host immune system. This can be seen in cases of chronic inflammatory diseases such as inflammatory bowel disease. A study has indicated the potential of receptors MC1R, MC3R, MC4R, and MC5R in regulating host inflammatory response. The inflammatory cells express melanocortin receptors. Monocytes, macrophages, lymphocytes, and microglia possess MC1R, MC3R, and MC5R. By modulating these receptors, scientists might be able to downregulate inflammatory pathways even in the presence of proinflammatory mediators such as cytokine interferon-gamma, TNF-alpha, IL-1, IL-6, IL-8, and growth-regulated oncogene-alpha. Naturally occurring Alpha-MSH may establish anti-inflammatory potential in several ways, such as: Downregulating IL-8 receptors and non-cytokine mediators, e.g., NO2 and iNOS. Reduction in migration of inflammatory cells and cell-adhesion molecule expression Enhancing the activity of anti-inflammatory cytokine IL-10 Inhibition of NF_kB proinflammatory pathway Reduction in chemotaxis of neutrophils by inhibiting superoxide radical production MC1R plays a significant role in various chronic inflammatory diseases by regulating the immune system to combat proinflammatory mediators. MC1R agonists may potentially improve blood-brain barrier efficiency and prevent penetration of inflammatory cells into the CNS. This is of great value in neuroinflammatory diseases such as multiple sclerosis. Another mechanism by which melanocortin receptors (mainly MC3R and MC4R) appear to express anti-inflammatory impact is a cholinergic anti-inflammatory pathway through the vagus nerve and alpha-7 receptors. This plays its role in ischemic brain and heart conditions and autoimmune regulation.

The most comprehensive human data on Melanotan-2 for skin pigmentation comes from University of Arizona dermatology trials conducted between 1996 and 2000, published in JAMA Dermatology and Archives of Dermatology. In a randomized, double-blind, placebo-controlled Phase I trial involving 10 subjects (Fitzpatrick skin types I–III), subcutaneous Melanotan-2 at 0.16 mg/kg over 10 days produced mean L* chromameter reductions of 6.2 units on non-UV-exposed skin (inner arm) vs 0.3 units for placebo. A statistically significant difference (p < 0.001). L* values measure skin lightness on a 0–100 scale; a 6-point reduction represents visible pigmentation equivalent to moderate sun exposure over 2–3 weeks. Dose-response curves from that trial showed threshold effects: doses below 0.025 mg/kg per injection produced minimal pigmentation, while doses above 0.08 mg/kg produced no additional melanogenic benefit but significantly increased nausea and flushing. The optimal range identified was 0.05–0.08 mg/kg administered every 48 hours for 10–14 days. For a 70 kg individual, that translates to 3.5–5.6 mg per injection. Pigmentation onset occurred 5–7 days after the first dose, reached maximum intensity at 14–21 days, and began fading at approximately 35 days post-final injection. A separate 2000 trial published in Archives of Dermatology examined photoprotection endpoints. Subjects (n=18, Fitzpatrick I–II) received Melanotan-2 0.16 mg/kg over 14 days, then underwent minimal erythema dose (MED) testing. The UV dose required to produce visible redness 24 hours post-exposure. Melanotan-2-treated subjects demonstrated MED increases of 2.1–2.8 fold vs baseline, meaning they required 2–3× the UV dose to produce the same level of sunburn. This photoprotective effect correlated directly with melanin density increases measured via reflectance spectroscopy, confirming that Melanotan-2-induced pigmentation provides functional UV absorption, not just cosmetic darkening. Adverse events in clinical trials were dose-dependent and transient. Nausea occurred in 40–60% of subjects at doses above 0.1 mg/kg, typically resolving within 2–4 hours. Facial flushing and mild hypertension (systolic increase 8–12 mmHg) occurred in 20–30% of subjects, attributed to peripheral vasodilation from melanocortin receptor activation. Spontaneous erections in male subjects occurred in 65–70% at pigmentation-inducing doses. A finding that led Palatin Technologies to discontinue photoprotection development and repurpose the peptide scaffold as bremelanotide (PT-141) for erectile dysfunction, which received FDA approval in 2019. Long-term safety data beyond 12 months is limited because FDA trials were halted in 2000. Post-market observational data from unregulated use. Primarily bodybuilding and tanning communities. Suggests that melanocytic nevi (moles) may darken or increase in number with prolonged Melanotan-2 exposure, raising theoretical melanoma concerns. No controlled long-term oncology studies exist. Researchers at institutions investigating melanocortin pathways should note that Melanotan-2 is not FDA-approved for any indication and remains classified as an investigational peptide under DEA and FDA oversight.